Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

South-East Asia Type 2 Diabetes Mellitus Therapeutics in Markets to 2022 - Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth - Research and Markets

Research and Markets
Posted on: 15 Sep 16

Research and Markets has announced the addition of the "Type 2 Diabetes Mellitus Therapeutics in South-East Asia Markets to 2022 - Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth" report to their offering.

T2DM treatment has been revolutionized in the past decade, especially with the increased use of new therapies. The marketed products landscape comprises a wide range of treatment options, including biguanide (metformin), sulfonylureas, thiazolidinediones, GLP-1 receptor agonists, DPP-4 inhibitors, SGLT-2 inhibitors, and insulin therapies. Nevertheless, significant unmet need remains for products that can offer better glycemic control, as well as the prevention and cure of diabetic complications, such as diabetic nephropathy, retinopathy, and cardiovascular disease.

Scope

The current South-East Asia T2DM market contains novel products, including Jardiance, a SGLT-2 inhibitor; Victoza, a GLP-1 receptor agonist; and Januvia, a DPP-4 inhibitor.

  • What are the competitive advantages of the existing novel drugs?

With over 500 active pipeline molecules, most of the late-stage investigational drug candidates are being evaluated, featuring improved dosing regimens and administration routes in comparison to currently marketed products and combination therapies.

  • Which classes of novel drugs are most prominent within the pipeline?
  • Is there strong potential for the pipeline to address unmet needs within the T2DM market?

Analysis of clinical trials since 2006 identified that the failure rates of T2DM molecules were highest in Phase III, at 49%, with the overall attrition rate for T2DM standing at 75%.

  • How do failure rates vary by product stage of development, molecule type, and mechanism of action?
  • How do other factors, such as average trial duration and trial size, influence the costs and risks associated with product development?

Over the 2015-2022 forecast period, the South-East Asia T2DM therapeutics market is expected to increase in value at a CAGR of 7.1%, from $1.7 billion to over $2.7 billion.

  • Which markets make the most significant contribution to the current market size?
  • What are the epidemiology trends in these markets?
  • Will new market entrants lead to substantial changes in annual therapy costs?
  • How will different treatment usage patterns impact growth in the eight assessed South-East Asia markets?

Rising T2DM prevalence and the uptake of newer therapies will lead to significant market growth over the forecast period, despite generic sales erosion resulting from patent expirations.

  • Will patent expirations or emerging pipeline molecules threaten the commercial success of existing drugs?

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Marketed Products

3.1 Overview

3.2 Biguanides

3.3 Sulfonylureas

3.4 Thiazolidinediones

3.5 GLP-1 Receptor Agonists

3.6 DPP-4 Inhibitors

3.7 SGLT-2 Inhibitors

3.8 Insulin Therapies

3.9 Comparative Efficacy and Safety of Marketed Products

4 Pipeline

4.1 Overview

4.2 Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type

4.3 Pipeline by Molecular Target

4.4 Promising Pipeline Candidates

4.5 Comparative Efficacy and Safety of Pipeline Products

4.6 Product Competitive Framework

5 Clinical Trial Analysis

6 Multi-Scenario Forecast

7 Market Dynamics, (Drivers and Barriers)

7.1 Drivers

7.1.1 Aging Population, Increasing Obesity and Growing Economy

7.1.2 Increasing Awareness of T2DM

7.1.3 Continued Uptake of Recently Approved Drug Classes

7.1.4 Promising Late-Stage Pipeline Products can Change the Treatment Paradigm

7.1.5 Enhanced Usage of Combination Therapies

7.2 Barriers

7.2.1 Non-pharmacological First-line Treatment

7.2.2 Widespread Usage of Generic Drugs

7.2.3 Poor Adherence to Treatment Regimens

7.2.4 Generic Erosion Resulting from Patent Expirations

8 Deals and Strategic Consolidations

8.1 Licensing Deals

8.2 Co-development Deals

9 Appendix

For more information about this report visit http://www.researchandmarkets.com/research/v2gwgl/type_2_diabetes

Related Topics: Endocrine and Metabolic Disorder Drugs, Endocrinology

About Research and Markets

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160915005692/en/

Business Wire
www.businesswire.com

Last updated on: 15/09/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.